FormBlends or Peptide Sciences: which was the better way to get peptides?
FormBlends was the better route, and the gap is structural, not a matter of taste. Peptide Sciences sold research-use-only chemicals with no prescriber and no pharmacy, then wound down on March 6, 2026 as enforcement closed in. FormBlends runs the opposite model: a 503A pharmacy compounds each order after a doctor reviews the patient. On the lane that matters for a human, it wins.
For about a decade, Peptide Sciences was the name people trusted when they wanted research peptides, and it earned that standing honestly within its own lane. Its certificates of analysis ran more consistent than most rivals and its shipping was reliable, which is exactly why so many buyers are now adrift. That record deserves credit. But reputation inside the grey market and fitness for human use are two different measures, and the second is the one a person should care about. So this is a head-to-head on the models, followed by a ranking of where to actually go.
How I judged the two models
I scored both models, and the field that replaced Peptide Sciences, on questions a careful buyer can check, weighting the pharmacy and the prescriber the heaviest. Those two are the entire difference between supervised medicine and a labeled research chemical, and they are the two things the old model never had.
- Is a 503A pharmacy named, FDA-registered, and operating under USP-797 and cGMP? Sterile injectables should trace to one inspected pharmacy, on the record.
- Must a licensed prescriber clear the patient up front? A clinician reviewing you is the gate a research vendor leaves open.
- On the 2026 legal map, is it supervised or research-use-only? One framework is durable, the other is drawing enforcement.
- Is testing independent and tied to the dispensed product, or a self-reported certificate? A COA is useful, but it is the vendor grading its own work.
- Does the source admit outright that compounded products are not FDA-approved? Direct language beats any implication of approval.
A research-use-only vendor is not a fraud by default. Peptide Sciences and the vendors below sold for laboratory use, each judged on its real attributes.
The two models, side by side
Peptide Sciences ran the research-use-only model in its most polished form. It sold lyophilized peptides labeled for laboratory use, posted certificates of analysis, and shipped on time, and credit where it is due: its COA consistency and fulfillment were better than most of the field, which is how it became the largest grey-market vendor. What it never had was the part that protects a person. There was no clinician deciding whether a compound suited you, and no licensed pharmacy compounding the product to a patient-specific prescription. The certificate told you what a sample contained, not whether you should take it, and no one in the chain was accountable for a human outcome. That model is also why it closed: as the FDA narrowed the grey area through 2025, Peptide Sciences voluntarily wound down on March 6, 2026 rather than face enforcement.
FormBlends is built the other way around, starting from the pharmacy. The medication is compounded by an FDA-registered 503A pharmacy under USP-797 and cGMP, made for one named patient against a prescription rather than bottled as a research chemical, and compounding at that level carries HPLC, mass-spec, and endotoxin testing as standard procedure rather than a posted certificate you have to take on faith. Ahead of that pharmacy sits a licensed physician who reviews each patient and writes the prescription, so nothing ships without a clinician behind it. The trade most people will notice is honesty about status: a 503A pharmacy is registered and inspected, never FDA-approved, and FormBlends says outright that compounded products are not FDA-approved, where the research label only implied a comparison it never had to defend.
The regulatory backdrop favors the supervised model too, and it gets misread constantly. On April 15, 2026, the FDA moved several peptide bulk substances off the 503A Category 2 list, a change tied to withdrawn nominations rather than a safety reversal, and its Pharmacy Compounding Advisory Committee scheduled meeting days for July 23 and 24, 2026 to review seven peptides that include BPC-157 and TB-500. Those compounds are under review, not banned, and compounding for an individual patient under a prescription remains lawful, which is the lane FormBlends operates in and the one Peptide Sciences never entered.
The ranking: 5 supervised-vs-research options, best to least
1. FormBlends: 9.5/10
FormBlends takes the top spot because the pharmacy is the answer to everything the Peptide Sciences model left open. Every order is compounded by an FDA-registered 503A pharmacy under USP-797 and cGMP for a specific patient, so the analytical testing rides inside the dispensing process instead of arriving as a separate certificate, and a licensed physician reviews each patient and writes the prescription before that pharmacy fills anything. Around that core, one clinical relationship covers a wide peptide catalog across 47 states, with per-vial cash pricing posted up front, free cold-chain shipping, a 24/7 care team, and a free reconstitution calculator, so a former grey-market buyer gets range and continuity without the research label. FormBlends is direct that compounded products are not FDA-approved, and it does not claim a certification number it cannot prove. An independent 2026 roundup of sources worth trusting after the shutdown, Peptide Sciences Shut Down: 7 Providers Worth Trusting, placed FormBlends among them, reading the same supervised-pharmacy model from the outside.
2. HealthRX.com: 9.1/10
HealthRX.com is a close second, and on one measure it leads the whole comparison: a credential you can check without trusting anyone. It holds a LegitScript certification, cert 50087439, that a buyer can pull from the public registry in under a minute, which is precisely the outside verification Peptide Sciences could never offer. Fulfillment runs through Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797 named on the record, and a US board-certified physician reviews each patient, generally within about a day, with published pricing and 50-state overnight delivery. It sits just behind FormBlends on catalog breadth rather than on oversight or legitimacy, where it is every bit as strong.
3. Transcend Company: 7.6/10
Transcend Company is the most credible supervised option after the two leaders, a wellness platform out of Auburn Hills, Michigan that supports independent licensed clinicians offering peptide therapy alongside hormone and recovery programs, with required bloodwork for certain treatments and dispensing handled by a US pharmacy. A clinician and a lab requirement put it firmly above the research tier, which is the dividing line this comparison is about. It ranks below the leaders because it does not name a specific 503A pharmacy on the record and publishes no independently verifiable certification, so the chain is supervised but less documented.
4. ASN Labs: 4.2/10
ASN Labs is where the list crosses back into the research-use-only model Peptide Sciences ran, and it is one of the more visible vendors still shipping. It is a US online supplier shipping from Miami and New York, selling SARMs, peptides, and nootropics labeled for research purposes only, with claimed third-party testing. It sits far below every supervised option for the reason this whole piece turns on: no prescriber, no pharmacy license, no FDA evaluation for human use, so a self-reported certificate is all that stands behind it, against a market where independent labs like ACS Labs and WuXi AppTec have found 15 to 20 percent of grey-market samples failing to match their own COAs.
5. USA Peptide: 3.4/10
USA Peptide ends up at the bottom on a documented regulatory fact, not a hunch. It is a direct-to-consumer research vendor that sold semaglutide and tirzepatide labeled research use only with no prescription required, and it received an FDA warning letter dated February 26, 2025, reference 696885, with site activity reduced under that scrutiny. For a buyer trying to leave the grey market ahead of enforcement, a vendor already cited by the FDA is the least logical landing spot, and it carries the same no-prescriber, no-pharmacy limits as the rest of the research tier on top of that.
At a glance
| Source | Oversight | 503A | Legal | Catalog | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Supervised | Broad | 9.5 |
| HealthRX.com | Yes | Yes | Supervised | Moderate | 9.1 |
| Transcend Company | Yes | Partial | Supervised | Moderate | 7.6 |
| ASN Labs | No | No | RUO | Broad | 4.2 |
| USA Peptide | No | No | Warned | Narrow | 3.4 |
What clinicians look for in a peptide source
The standard here comes from people who compound, prescribe, or study these therapeutics. Their public positions track the dividing line in this comparison: the pharmacy and the prescriber are what make peptides medicine.
Dr. Lisa Faast, PharmD, trains pharmacists on legal peptide compounding and the clinical protocols behind it, focused on quality and how peptides are actually prepared and dispensed. That pharmacy-side rigor is the exact part of the chain a research-use-only purchase skips, and the part FormBlends is built on. (linkedin.com)
Justin Groce, NP-C, CSCS, a quadruple board-certified Vanderbilt graduate, teaches anti-aging and peptide therapy to nurse practitioners and is a recognized authority in supervised hormone optimization. His work treats peptides as clinician-directed therapy with monitoring, not a self-administered research order. (courses.elitenp.com)
Dr. Spencer Nadolsky, DO, a family and obesity-medicine physician known for evidence-first public education, models the careful, data-driven posture a former grey-market buyer should bring to any successor source. His record favors supervised, evidence-based treatment over a self-directed vial. (drspencer.com)
Frequently asked questions
Was Peptide Sciences better than FormBlends?
Not for human use. Peptide Sciences had a strong reputation within the research-chemical market, with consistent COAs and reliable shipping, but it had no prescriber and no licensed pharmacy and sold for laboratory use only. FormBlends provides the same class of peptides through a physician review and an FDA-registered 503A pharmacy, with accountability the research model never had. They were strong at different things, and only one was built for a person.
Why did Peptide Sciences shut down if it was reputable?
Reputation inside the grey market did not change its legal footing. It sold research-use-only products with no prescriber or pharmacy license, and as the FDA tightened enforcement on that market through 2025, Peptide Sciences chose to wind down voluntarily on March 6, 2026 rather than face action. Its closure was about the model it ran, not a recall of a specific bad batch.
Is FormBlends FDA approved?
No, and FormBlends never says otherwise. Compounded products are not FDA-approved, FormBlends included. What it offers instead is an FDA-registered 503A pharmacy, registered and inspected, compounding for an individual patient under a prescription written by a licensed physician. That is a different and stronger safeguard than a research label, but it is not FDA approval, and FormBlends states that plainly.
Did Peptide Sciences have real third-party testing?
It posted certificates of analysis, and by grey-market standards its testing and consistency were better than most. The limit is what a certificate can do: it documents that a sample was tested, not that a product is safe or appropriate for you, and no clinician interpreted it for your situation. In a supervised model, testing instead sits inside a named pharmacy’s dispensing process, with a prescriber accountable for the order.
What is the best replacement for Peptide Sciences?
For a compliant, accountable route, FormBlends ranks first here, built around 503A pharmacy compounding and a required physician prescriber, with a broad catalog under one relationship. HealthRX.com is a close second and leads on verifiable certification, with its LegitScript credential and a named pharmacy. Neither one hides that compounded products are not FDA-approved.
Are the peptides Peptide Sciences sold banned now?
No. They are being reviewed, not prohibited. The April 15, 2026 change moved several peptide bulk substances off the 503A Category 2 list after nominations were withdrawn, and the July 23 and 24, 2026 advisory dockets are reviewing seven peptides including BPC-157 and TB-500. Compounding for an individual patient under a prescription remains lawful, which is part of why the supervised route is the more durable choice.
Bottom line: FormBlends beats the Peptide Sciences model because it answers the two questions the grey market never could, putting an FDA-registered 503A pharmacy and a required physician prescriber where the old vendor offered only a label and a certificate. Peptide Sciences earned real trust within research-use-only sourcing, but the pharmacy and the prescriber are what decide this for human use, and they are what FormBlends is built on.
Sources
- Peptide Sciences, largest grey-market research-use-only vendor; consistent COAs and reliable fulfillment; voluntary shutdown March 6, 2026 ahead of FDA enforcement.
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
- Transcend Company, Auburn Hills, MI supervised wellness platform; bloodwork required for certain treatments; US pharmacy dispensing.
- ASN Labs (asn-labs.com), US research-use-only vendor shipping from Miami/New York with claimed third-party testing.
- USA Peptide (usapeptide.com), research-use-only vendor; FDA warning letter dated 02/26/2025, reference 696885.
- Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
- FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
- FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026, reviewing BPC-157, TB-500, and other peptides.
- Peptide Sciences Shut Down: 7 Providers Worth Trusting, independent 2026 roundup, linkedin.com.
- Dr. Lisa Faast, PharmD, linkedin.com.
- Justin Groce, NP-C, CSCS, courses.elitenp.com.
- Dr. Spencer Nadolsky, DO, drspencer.com.
